METHOD FOR TREATING AND PREVENTING HYPERPARATHYROIDISM
First Claim
Patent Images
1. A method of treating hyperparathyroidism comprising administering to a subject suffering there from an amount of an active vitamin D compound of formula (I):
-
wherein A1 and A2 each are hydrogen or together represent a carbon-carbon bond, thus forming a double bond between C-22 and C-23;
R1 and R2 are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that both R1 and R2 cannot both be an alkenyl, or taken together with the carbon to which they are bonded, form a C3-C8 cyclocarbon ring;
R3 is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl;
X1 is hydrogen or hydroxyl;
X2 is hydrogen or hydroxyl, or, is taken with R1 or R2, to constitute a double bond;
X3 is hydrogen or hydroxyl provided that at least one of X1, X2 and X3 is hydroxyl;
wherein the active vitamin D is administered in a single dose of between about 100 μ
g to about 300 μ
g on an episodic basis, wherein the single dose is given at periodic intervals varying from once every two weeks to once every 12 weeks; and
wherein the dose of vitamin D administered is sufficient to lower elevated or maintain lowered blood parathyroid hormone levels in the subject, with reduced risk of hypercalcemia.
0 Assignments
0 Petitions
Accused Products
Abstract
This invention relates to a method for treating or preventing hyperthyroidism associated with aging and/or with Aging-Related Vitamin D Deficiency (ARVDD) syndrome by administering a sufficient amount of an active vitamin D compound utilizing a variety of effective treatment protocols. The invention further relates to treating or preventing one or more of the following conditions, e.g., (1) primary vitamin D deficiency, (2) 1,25-(OH)2D3 deficiency, and (3) 1,25-(OH)2D3 resistance included within the syndrome of ARVDD.
-
Citations
18 Claims
-
1. A method of treating hyperparathyroidism comprising administering to a subject suffering there from an amount of an active vitamin D compound of formula (I):
-
wherein A1 and A2 each are hydrogen or together represent a carbon-carbon bond, thus forming a double bond between C-22 and C-23;
R1 and R2 are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that both R1 and R2 cannot both be an alkenyl, or taken together with the carbon to which they are bonded, form a C3-C8 cyclocarbon ring;
R3 is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl;
X1 is hydrogen or hydroxyl;
X2 is hydrogen or hydroxyl, or, is taken with R1 or R2, to constitute a double bond;
X3 is hydrogen or hydroxyl provided that at least one of X1, X2 and X3 is hydroxyl;wherein the active vitamin D is administered in a single dose of between about 100 μ
g to about 300 μ
g on an episodic basis, wherein the single dose is given at periodic intervals varying from once every two weeks to once every 12 weeks; andwherein the dose of vitamin D administered is sufficient to lower elevated or maintain lowered blood parathyroid hormone levels in the subject, with reduced risk of hypercalcemia. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
-
-
10. A method of treating hyperparathyroidism comprising administering to a subject suffering there from an amount of an active vitamin D compound of formula (I):
-
wherein A1 and A2 each are hydrogen or together represent a carbon-carbon bond, thus forming a double bond between C-22 and C-23;
R1 and R2 are identical or different and are hydrogen, hydroxyl, lower alkyl, lower fluoroalkyl, O-lower alkyl, lower alkenyl, lower fluoroalkenyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl, lower cycloalkyl with the proviso that both R1 and R2 cannot both be an alkenyl, or taken together with the carbon to which they are bonded, form a C3-C8 cyclocarbon ring;
R3 is lower alkyl, lower alkenyl, lower fluoroalkyl, lower fluoroalkenyl, O-lower alkyl, O-lower alkenyl, O-lower acyl, O-aromatic acyl or lower cycloalkyl;
X1 is hydrogen or hydroxyl;
X2 is hydrogen or hydroxyl, or, is taken with R1 or R2, to constitute a double bond;
X3 is hydrogen or hydroxyl provided that at least one of X1, X2 and X3 is hydroxyl;wherein the active vitamin D is administered in a single dose of about 100 μ
g to about 300 μ
g on an episodic basis, wherein the single dose is given at periodic intervals varying from once a week to once every 12 weeks; andwherein the dose of vitamin D administered is sufficient to lower elevated or maintain lowered blood parathyroid hormone levels in the subject, with reduced risk of hypercalcemia. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
-
Current AssigneeJoyce C. Knutson, Richard B. Mazess, Stephen A. Strugnell
-
Original AssigneeJoyce C. Knutson, Richard B. Mazess, Stephen A. Strugnell
-
InventorsMazess, Richard B., Knutson, Joyce C., Strugnell, Stephen A.
-
Application NumberUS12/170,280Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current514/167CPC Class CodesA61K 2300/00 Mixtures or combinations of...A61K 31/565 not substituted in position...A61K 31/59 Compounds containing 9, 10-...A61K 31/592 9,10-Secoergostane derivati...A61K 31/593 9,10-Secocholestane derivat...A61K 31/663 Compounds having two or mor...A61K 31/714 Cobalamins, e.g. cyanocobal...A61K 33/16 Fluorine compoundsA61K 33/22 Boron compoundsA61K 45/06 Mixtures of active ingredie...A61P 19/10 for osteoporosisA61P 3/02 Nutrients, e.g. vitamins, m...A61P 43/00 Drugs for specific purposes...A61P 5/16 for decreasing, blocking or...A61P 5/18 of the parathyroid hormonesC07C 401/00 Irradiation products of cho...
